Item Type | Name |
Academic Article
|
Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer.
|
Academic Article
|
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
|
Academic Article
|
The role of relaxin in endometrial cancer.
|
Academic Article
|
Modified vertical rectus abdominis myocutaneous flap vaginal reconstruction: an analysis of surgical outcomes.
|
Academic Article
|
FOXM1 mediates Dox resistance in breast cancer by enhancing DNA repair.
|
Academic Article
|
Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma.
|
Academic Article
|
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
|
Academic Article
|
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer.
|
Academic Article
|
Pelvic fractures after radiotherapy for cervical cancer: implications for survivors.
|
Academic Article
|
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer.
|
Academic Article
|
Unmasking the complexities of mucinous ovarian carcinoma.
|
Academic Article
|
Photothermal-chemotherapy with doxorubicin-loaded hollow gold nanospheres: A platform for near-infrared light-trigged drug release.
|
Academic Article
|
Targeting SRC in mucinous ovarian carcinoma.
|
Academic Article
|
Proceedings from the 9th International Conference on Ovarian Cancer.
|
Academic Article
|
Paraneoplastic thrombocytosis in ovarian cancer.
|
Academic Article
|
Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.
|
Academic Article
|
Platelets increase the proliferation of ovarian cancer cells.
|
Concept
|
Genital Neoplasms, Female
|
Concept
|
Female
|
Academic Article
|
CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer.
|
Academic Article
|
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA.
|
Academic Article
|
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.
|
Academic Article
|
Impact of cardiovascular comorbidity on ovarian cancer mortality.
|
Academic Article
|
Targeting SRC and tubulin in mucinous ovarian carcinoma.
|
Academic Article
|
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth.
|
Academic Article
|
Src activation by ?-adrenoreceptors is a key switch for tumour metastasis.
|
Academic Article
|
Integrated genomic analyses of ovarian carcinoma.
|
Academic Article
|
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer.
|
Academic Article
|
Summary of the 2014 MD Anderson International Meeting in Gynecologic Oncology: emerging therapies in gynecologic cancer.
|
Academic Article
|
Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer.
|
Academic Article
|
Rethinking ovarian cancer: recommendations for improving outcomes.
|
Academic Article
|
Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers.
|
Academic Article
|
Surgical management of cervical cancer complicating pregnancy: a case-control study.
|
Academic Article
|
Radiotherapeutic management of cervical carcinoma that complicates pregnancy.
|
Academic Article
|
Preservation of the saphenous vein during inguinal lymphadenectomy decreases morbidity in patients with carcinoma of the vulva.
|
Academic Article
|
Hormone replacement therapy and cancer risk.
|
Academic Article
|
Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma.
|
Academic Article
|
Quality of life and mood in women with gynecologic cancer: a one year prospective study.
|
Academic Article
|
Postoperative wound infection with Pasteurella multocida from a pet cat.
|
Academic Article
|
Serum CA 125 is an independent prognostic factor in cervical adenocarcinoma.
|
Academic Article
|
The complexity of tumor vascularity.
|
Academic Article
|
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
|
Academic Article
|
Location matters.
|
Academic Article
|
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
|
Academic Article
|
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
|
Academic Article
|
Analysis of EphA2 expression and mutant p53 in ovarian carcinoma.
|
Academic Article
|
Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma.
|
Academic Article
|
Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism.
|
Academic Article
|
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma.
|
Academic Article
|
Classification of ovarian cancer: a genomic analysis.
|
Academic Article
|
Dual targeting of EphA2 and FAK in ovarian carcinoma.
|
Academic Article
|
Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients.
|
Academic Article
|
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
|
Academic Article
|
Frequent downregulation of miR-34 family in human ovarian cancers.
|
Academic Article
|
Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer.
|
Academic Article
|
Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.
|
Academic Article
|
Distinctive DNA methylation patterns of cell-free plasma DNA in women with malignant ovarian tumors.
|
Academic Article
|
Therapeutic advances in women's cancers.
|
Academic Article
|
Microenvironment and pathogenesis of epithelial ovarian cancer.
|
Academic Article
|
Targeting angiogenesis in gynecologic cancers.
|
Academic Article
|
Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
|
Academic Article
|
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
|
Academic Article
|
p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation.
|
Academic Article
|
Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3.
|
Academic Article
|
Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
|
Academic Article
|
Importance of adrenergic pathways in women's cancers.
|
Academic Article
|
EDD enhances cell survival and cisplatin resistance and is a therapeutic target for epithelial ovarian cancer.
|
Academic Article
|
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib.
|
Academic Article
|
MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer.
|
Academic Article
|
Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.
|
Academic Article
|
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.
|
Academic Article
|
Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
|
Academic Article
|
An abundance of p53 null mutations in ovarian carcinoma.
|
Academic Article
|
Ovarian cancer genomic instability correlates with p53 frameshift mutations.
|
Academic Article
|
The use of chemotherapeutic agents during pregnancy.
|
Academic Article
|
Taxol hypersensitivity: rapid retreatment is safe and cost effective.
|
Academic Article
|
Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
|
Academic Article
|
Cervical cancer diagnosed shortly after pregnancy: prognostic variables and delivery routes.
|
Academic Article
|
Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.
|
Academic Article
|
Quality of life and mood in women receiving extensive chemotherapy for gynecologic cancer.
|
Academic Article
|
Longterm central venous access in gynecologic cancer patients.
|
Academic Article
|
Recurrent carcinoma in situ of a neovagina.
|
Academic Article
|
Molecular determinants of ovarian cancer plasticity.
|
Academic Article
|
p53 Mutations and microsatellite instability in ovarian cancer: Yin and yang.
|
Academic Article
|
The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer.
|
Academic Article
|
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.
|
Academic Article
|
Vascular endothelial growth factor and social support in patients with ovarian carcinoma.
|
Academic Article
|
The paradoxical expression of maspin in ovarian carcinoma.
|
Academic Article
|
Operative note dictation: should it be taught routinely in residency programs?
|
Academic Article
|
Late recurrence of juvenile granulosa cell tumor of the ovary.
|
Academic Article
|
EphA2 expression is associated with aggressive features in ovarian carcinoma.
|
Academic Article
|
Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.
|
Academic Article
|
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer.
|
Academic Article
|
Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
|
Academic Article
|
The merits of vascular targeting for gynecologic malignancies.
|
Academic Article
|
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
|
Academic Article
|
Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
|
Academic Article
|
Stress hormone-mediated invasion of ovarian cancer cells.
|
Academic Article
|
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer.
|
Academic Article
|
Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer.
|
Academic Article
|
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
|
Academic Article
|
EphA2 overexpression is associated with angiogenesis in ovarian cancer.
|
Academic Article
|
Second look laparotomy for ovarian germ cell tumors: to do or not to do?
|
Academic Article
|
The neuroendocrine impact of chronic stress on cancer.
|
Academic Article
|
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
|
Academic Article
|
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
|
Academic Article
|
Positive psychosocial factors and NKT cells in ovarian cancer patients.
|
Academic Article
|
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
|
Academic Article
|
Neuroendocrine modulation of signal transducer and activator of transcription-3 in ovarian cancer.
|
Academic Article
|
Angiogenesis as a strategic target for ovarian cancer therapy.
|
Academic Article
|
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma.
|
Academic Article
|
Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients.
|
Academic Article
|
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
|
Academic Article
|
Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
|
Academic Article
|
Targeted therapy in gynecologic oncology: biology, strategy, and assessment.
|
Academic Article
|
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
|
Academic Article
|
Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
|
Academic Article
|
EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma.
|
Academic Article
|
Sustained small interfering RNA delivery by mesoporous silicon particles.
|
Academic Article
|
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
|
Academic Article
|
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer.
|
Academic Article
|
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.
|
Academic Article
|
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles.
|
Academic Article
|
Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
|
Academic Article
|
Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer.
|
Academic Article
|
New roles opined for OPCML.
|
Academic Article
|
Social influences on clinical outcomes of patients with ovarian cancer.
|
Academic Article
|
Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.
|
Academic Article
|
Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability.
|
Academic Article
|
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
|
Academic Article
|
Genomic DNA copy-number alterations of the let-7 family in human cancers.
|
Academic Article
|
A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: a Gynecologic Oncology Group study.
|
Academic Article
|
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer.
|
Academic Article
|
Tat-activating regulatory DNA-binding protein regulates glycolysis in hepatocellular carcinoma by regulating the platelet isoform of phosphofructokinase through microRNA 520.
|
Academic Article
|
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer.
|
Academic Article
|
Interleukin-1? promotes ovarian tumorigenesis through a p53/NF-?B-mediated inflammatory response in stromal fibroblasts.
|
Academic Article
|
ATP11B mediates platinum resistance in ovarian cancer.
|
Academic Article
|
Neighborhood matters: response to EZH2 methyltransferase inhibitors.
|
Academic Article
|
Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.
|
Academic Article
|
Tumour angiogenesis regulation by the miR-200 family.
|
Academic Article
|
Non-cancer life stressors contribute to impaired quality of life in ovarian cancer patients.
|
Academic Article
|
A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation.
|
Academic Article
|
Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma.
|
Academic Article
|
Balancing GRK2 and EPAC1 levels prevents and relieves chronic pain.
|
Academic Article
|
Cystathionine beta-synthase (CBS) contributes to advanced ovarian cancer progression and drug resistance.
|
Academic Article
|
Perioperative beta-blocker use and survival in lung cancer patients.
|
Academic Article
|
Activation of YAP1 is associated with poor prognosis and response to taxanes in ovarian cancer.
|
Academic Article
|
Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma.
|
Academic Article
|
Platelet effects on ovarian cancer.
|
Academic Article
|
Hematogenous metastasis of ovarian cancer: rethinking mode of spread.
|
Academic Article
|
miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.
|
Academic Article
|
Anaphylaxis to carboplatin following multiple previous uncomplicated courses.
|
Academic Article
|
Prediction of fetal macrosomia using humeral soft tissue thickness.
|
Academic Article
|
Genomic instability in ovarian cancer: a reassessment using an arbitrarily primed polymerase chain reaction.
|
Academic Article
|
Posterior exenteration through groin incision in a patient with stage III vulvar carcinoma.
|
Academic Article
|
Value of preoperative CA 125 level in the management of uterine cancer and prediction of clinical outcome.
|
Academic Article
|
Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction.
|
Academic Article
|
Field cancerization: why late "recurrent" ovarian cancer is not recurrent.
|
Academic Article
|
Re: Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer.
|
Academic Article
|
Hematogenous skin metastases from cervical cancer at primary presentation.
|
Academic Article
|
The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
|
Academic Article
|
Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer.
|
Academic Article
|
Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy.
|
Academic Article
|
Preoperative CA 125 levels: an independent prognostic factor for epithelial ovarian cancer.
|
Academic Article
|
Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study.
|
Academic Article
|
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines.
|
Academic Article
|
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma.
|
Academic Article
|
Docetaxel versus paclitaxel for adjuvant treatment of ovarian cancer: case-control analysis of toxicity.
|
Academic Article
|
Comment on "Recurrent carcinoma in situ of a neovagina".
|
Academic Article
|
Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.
|
Academic Article
|
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
|
Academic Article
|
Malignant mixed mullerian tumor (MMMT) of the cervix.
|
Academic Article
|
Social support, psychological distress, and natural killer cell activity in ovarian cancer.
|
Academic Article
|
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
|
Academic Article
|
The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.
|
Academic Article
|
Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma.
|
Academic Article
|
Historical progress in the initial management of ovarian cancer: intraperitoneal chemotherapy.
|
Academic Article
|
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
|
Academic Article
|
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
|
Academic Article
|
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.
|
Academic Article
|
Supracervical hysterectomy in patients with advanced epithelial ovarian cancer.
|
Academic Article
|
Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
|
Academic Article
|
Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.
|
Academic Article
|
Markers of angiogenesis in ovarian cancer.
|
Academic Article
|
Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
|
Academic Article
|
Early events in the pathogenesis of epithelial ovarian cancer.
|
Academic Article
|
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
|
Academic Article
|
EphA2 overexpression promotes ovarian cancer growth.
|
Academic Article
|
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer.
|
Academic Article
|
Highlights from the 2008 Annual Meeting of the American Association for Cancer Research.
|
Academic Article
|
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.
|
Academic Article
|
Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer.
|
Academic Article
|
Glucose as a prognostic factor in ovarian carcinoma.
|
Academic Article
|
Patterns of metastasis in sex cord-stromal tumors of the ovary: can routine staging lymphadenectomy be omitted?
|
Academic Article
|
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
|
Academic Article
|
Estrous cycle modulates ovarian carcinoma growth.
|
Academic Article
|
Liposomal siRNA for ovarian cancer.
|
Academic Article
|
Aflibercept in epithelial ovarian carcinoma.
|
Academic Article
|
Novel strategies for reversing platinum resistance.
|
Academic Article
|
Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
|
Academic Article
|
Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma.
|
Academic Article
|
Farletuzumab in epithelial ovarian carcinoma.
|
Academic Article
|
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.
|
Academic Article
|
Regulation of tumor angiogenesis by EZH2.
|
Academic Article
|
Overcoming platinum resistance in ovarian carcinoma.
|
Academic Article
|
The sympathetic nervous system induces a metastatic switch in primary breast cancer.
|
Academic Article
|
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis.
|
Academic Article
|
Multidrug resistance gene (MDR-1) and risk of brain metastasis in epithelial ovarian, fallopian tube, and peritoneal cancer.
|
Academic Article
|
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer.
|
Academic Article
|
Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients.
|
Academic Article
|
Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing.
|
Academic Article
|
Functional roles of Src and Fgr in ovarian carcinoma.
|
Academic Article
|
Supporting gynecologic cancer research: the last 20 years and beyond.
|
Academic Article
|
Chitosan hydrogel for localized gene silencing.
|
Academic Article
|
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer.
|
Academic Article
|
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
|
Academic Article
|
Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
|
Academic Article
|
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.
|
Academic Article
|
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
|
Academic Article
|
Prognostic biomarkers in ovarian cancer.
|
Academic Article
|
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance.
|
Academic Article
|
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer.
|
Academic Article
|
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer.
|
Academic Article
|
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma.
|
Academic Article
|
Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
|
Academic Article
|
Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors.
|
Academic Article
|
Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer.
|
Academic Article
|
Contemporary use of bevacizumab in ovarian cancer.
|
Academic Article
|
Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer.
|
Academic Article
|
Latest research and treatment of advanced-stage epithelial ovarian cancer.
|
Academic Article
|
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery.
|
Academic Article
|
Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis.
|
Academic Article
|
Poor survival with wild-type TP53 ovarian cancer?
|
Academic Article
|
A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.
|
Academic Article
|
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer.
|
Academic Article
|
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer.
|
Academic Article
|
Autocrine effects of tumor-derived complement.
|
Academic Article
|
The influence of the p53 codon 72 polymorphism on ovarian carcinogenesis and prognosis.
|
Academic Article
|
Invasive cervical cancer complicating pregnancy. How to manage the dilemma.
|
Academic Article
|
Drug resistance in ovarian cancer: from the laboratory to the clinic.
|
Academic Article
|
Distant metastases in ovarian cancer: association with p53 mutations.
|
Academic Article
|
Ovarian cancer p53 mutation is associated with tumor microvessel density.
|
Academic Article
|
Genomic instability is associated with lack of telomerase activation in ovarian cancer.
|
Academic Article
|
Novel modification of the vertical rectus abdominis myocutaneous flap for neovagina creation.
|
Academic Article
|
Fifth International Conference on Ovarian Cancer: challenges and opportunities.
|
Academic Article
|
Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
|
Academic Article
|
Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer.
|
Academic Article
|
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.
|
Academic Article
|
Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma.
|
Academic Article
|
Functional significance of VEGFR-2 on ovarian cancer cells.
|
Academic Article
|
Dicer, Drosha, and outcomes in patients with ovarian cancer.
|
Academic Article
|
Surgical stress promotes tumor growth in ovarian carcinoma.
|
Academic Article
|
EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer.
|
Academic Article
|
Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker.
|
Academic Article
|
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.
|
Academic Article
|
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
|
Academic Article
|
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
|
Academic Article
|
A novel platform for detection of CK+ and CK- CTCs.
|
Academic Article
|
Moving beyond VEGF for anti-angiogenesis strategies in gynecologic cancer.
|
Academic Article
|
Sleep disturbance, cytokines, and fatigue in women with ovarian cancer.
|
Academic Article
|
Integrated analysis of gene expression and tumor nuclear image profiles associated with chemotherapy response in serous ovarian carcinoma.
|
Academic Article
|
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
|
Academic Article
|
Inverse relationship between TCTP/RhoA and p53 /cyclin A/actin expression in ovarian cancer cells.
|
Academic Article
|
Notch3 pathway alterations in ovarian cancer.
|
Academic Article
|
Second-trimester vaginal bleeding: correlation of ultrasonographic findings with perinatal outcome.
|
Academic Article
|
Two successful pregnancies after conservative treatment of endometrial cancer and assisted reproduction.
|
Academic Article
|
Allopathic and complementary alternatives to hormone replacement therapy.
|
Academic Article
|
p53 null mutations are associated with a telomerase negative phenotype in ovarian carcinoma.
|
Academic Article
|
The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.
|
Academic Article
|
Implementation of assisted reproductive technologies following conservative management of FIGO grade I endometrial adenocarcinoma and/or complex hyperplasia with atypia.
|
Academic Article
|
Selected highlights from the 5th International Conference on Ovarian Cancer. Houston, TX, USA, 1-4 December 2004.
|
Academic Article
|
EphA2 as a target for ovarian cancer therapy.
|
Academic Article
|
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
|
Academic Article
|
Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR.
|
Academic Article
|
Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients.
|
Academic Article
|
Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
|
Academic Article
|
EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
|
Academic Article
|
Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
|
Academic Article
|
Targeted gene silencing using RGD-labeled chitosan nanoparticles.
|
Academic Article
|
Dopamine blocks stress-mediated ovarian carcinoma growth.
|
Academic Article
|
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers.
|
Academic Article
|
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
|
Academic Article
|
Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study.
|
Academic Article
|
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
|
Academic Article
|
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment.
|
Academic Article
|
TP53 loss creates therapeutic vulnerability in?colorectal cancer.
|
Academic Article
|
Electron cryotomography reveals ultrastructure alterations in platelets from patients with ovarian cancer.
|
Academic Article
|
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.
|
Academic Article
|
Significance of lymphovascular space invasion in epithelial ovarian cancer.
|
Academic Article
|
Biologic effects of dopamine on tumor vasculature in ovarian carcinoma.
|
Academic Article
|
2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity.
|
Academic Article
|
Biologic effects of platelet-derived growth factor receptor a blockade in uterine cancer.
|
Academic Article
|
MiR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma.
|
Academic Article
|
Antagonism of tumoral prolactin receptor promotes autophagy-related cell death.
|
Academic Article
|
Metronomic docetaxel in PRINT nanoparticles and EZH2 silencing have synergistic antitumor effect in ovarian cancer.
|
Academic Article
|
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
|
Academic Article
|
Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.
|
Academic Article
|
Effect of lymphovascular space invasion on survival of stage I epithelial ovarian cancer.
|
Academic Article
|
Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer.
|
Academic Article
|
The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.
|
Academic Article
|
Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma.
|
Academic Article
|
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer.
|
Academic Article
|
Calcium-dependent FAK/CREB/TNNC1 signalling mediates the effect of stromal MFAP5 on ovarian cancer metastatic potential.
|
Academic Article
|
Therapeutic silencing of KRAS using systemically delivered siRNAs.
|
Academic Article
|
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression.
|
Academic Article
|
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER.
|
Academic Article
|
Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer.
|
Academic Article
|
Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
|
Academic Article
|
Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.
|
Academic Article
|
Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion.
|
Academic Article
|
New ways to successfully target tumor vasculature in ovarian cancer.
|
Academic Article
|
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
|
Academic Article
|
Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer.
|
Academic Article
|
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer.
|
Academic Article
|
Diurnal cortisol and survival in epithelial ovarian cancer.
|
Academic Article
|
Preclinical and clinical development of siRNA-based therapeutics.
|
Academic Article
|
Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.
|
Academic Article
|
A framework for a personalized surgical approach to ovarian cancer.
|
Academic Article
|
Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth.
|
Academic Article
|
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.
|
Academic Article
|
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
|
Academic Article
|
XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A.
|
Academic Article
|
Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.
|
Academic Article
|
Biobehavioral and neuroendocrine correlates of antioxidant enzyme activity in ovarian carcinoma.
|
Academic Article
|
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
|
Academic Article
|
Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer.
|
Academic Article
|
The ZNF304-integrin axis protects against anoikis in cancer.
|
Academic Article
|
Eudaimonic well-being and tumor norepinephrine in patients with epithelial ovarian cancer.
|
Academic Article
|
CuS Nanodots with Ultrahigh Efficient Renal Clearance for Positron Emission Tomography Imaging and Image-Guided Photothermal Therapy.
|
Academic Article
|
Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
|
Academic Article
|
CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
|
Academic Article
|
State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer.
|
Academic Article
|
Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
|
Academic Article
|
Targeting c-MYC in Platinum-Resistant Ovarian Cancer.
|
Academic Article
|
Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
|
Academic Article
|
Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer.
|
Academic Article
|
Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma.
|
Academic Article
|
Reply to beta blockers in epithelial ovarian cancer and beta-blockers and improved survival from ovarian cancer: New miracle treatment or another case of immortal person-time bias?
|
Academic Article
|
Depression and risk of epithelial ovarian cancer: Results from two large prospective cohort studies.
|
Academic Article
|
Erythropoietin Stimulates Tumor Growth via EphB4.
|
Academic Article
|
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
|
Academic Article
|
Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
|
Academic Article
|
Depression and Oropharynx Cancer Outcome.
|
Academic Article
|
A genome-scale screen reveals context-dependent ovarian cancer sensitivity to miRNA overexpression.
|
Academic Article
|
Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis.
|
Academic Article
|
Assessment of In Vivo siRNA Delivery in Cancer Mouse Models.
|
Academic Article
|
Role of Increased n-acetylaspartate Levels in Cancer.
|
Academic Article
|
Carcinoma of the Bartholin Gland: A Review of 33 Cases.
|
Academic Article
|
Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
|
Academic Article
|
Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
|
Academic Article
|
A miR-192-EGR1-HOXB9 regulatory network controls the angiogenic switch in cancer.
|
Academic Article
|
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
|
Academic Article
|
miR-509-3p is clinically significant and strongly attenuates cellular migration and multi-cellular spheroids in ovarian cancer.
|
Academic Article
|
Platelets are not hyperreactive in patients with ovarian cancer.
|
Academic Article
|
Highly heterogeneous genomic landscape of uterine leiomyomas by?whole exome sequencing and genome-wide arrays.
|
Academic Article
|
Precision Nanomedicine Using Dual PET and MR Temperature Imaging-Guided Photothermal Therapy.
|
Academic Article
|
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.
|
Academic Article
|
PRKCI promotes immune suppression in ovarian cancer.
|
Academic Article
|
Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.
|
Academic Article
|
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers.
|
Academic Article
|
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
|
Academic Article
|
JAK2-binding long noncoding RNA promotes breast cancer brain metastasis.
|
Academic Article
|
HN1L Promotes Triple-Negative Breast Cancer Stem Cells through LEPR-STAT3 Pathway.
|
Academic Article
|
ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
|
Academic Article
|
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
|
Academic Article
|
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
|
Academic Article
|
A prospective study of phobic anxiety, risk of ovarian cancer, and survival among patients.
|
Academic Article
|
Prediction of anti-angiogenesis escape.
|
Academic Article
|
Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer.
|
Academic Article
|
Role of Video-Assisted Thoracoscopy in Advanced Ovarian Cancer: A Literature Review.
|
Academic Article
|
Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.
|
Academic Article
|
Complement Component 3 Is Regulated by TWIST1 and Mediates Epithelial-Mesenchymal Transition.
|
Academic Article
|
Targeting the tumour microenvironment in ovarian cancer.
|
Academic Article
|
Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma.
|
Academic Article
|
Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer.
|
Academic Article
|
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
|
Academic Article
|
Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer.
|
Academic Article
|
Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience.
|
Academic Article
|
NO-dependent attenuation of TPA-induced immunoinflammatory skin changes in Balb/c mice by pindolol, heptaminol or ATRA, but not by verapamil.
|
Academic Article
|
Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer.
|
Academic Article
|
Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer.
|
Academic Article
|
Ovarian cancer.
|
Academic Article
|
Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.
|
Academic Article
|
Association of Ovarian Tumor ?2-Adrenergic Receptor Status with Ovarian Cancer Risk Factors and Survival.
|
Academic Article
|
Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells.
|
Academic Article
|
Pathology in Practice.
|
Academic Article
|
RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.
|
Academic Article
|
TFEB ameliorates the impairment of the autophagy-lysosome pathway in neurons induced by doxorubicin.
|
Academic Article
|
MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancer.
|
Academic Article
|
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
|
Academic Article
|
Role of CTGF in Sensitivity to Hyperthermia in Ovarian and Uterine Cancers.
|
Academic Article
|
Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors.
|
Academic Article
|
Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA).
|
Academic Article
|
Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
|
Academic Article
|
MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis.
|
Academic Article
|
The rise of genomic profiling in ovarian cancer.
|
Academic Article
|
Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery.
|
Academic Article
|
A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience.
|
Academic Article
|
In vivo stepwise immunomodulation using chitosan nanoparticles as a platform nanotechnology for cancer immunotherapy.
|
Academic Article
|
Metastasis regulation by PPARD expression in cancer cells.
|
Academic Article
|
HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer.
|
Academic Article
|
Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
|
Academic Article
|
Role of Platelet-Derived Tgf?1 in the Progression of Ovarian Cancer.
|
Academic Article
|
miR-200c-driven Mesenchymal-To-Epithelial Transition is a Therapeutic Target in Uterine Carcinosarcomas.
|
Academic Article
|
The Association of Work Characteristics With Ovarian Cancer Risk and Mortality.
|
Academic Article
|
Metabolic Markers and Statistical Prediction of Serous Ovarian Cancer Aggressiveness by Ambient Ionization Mass Spectrometry Imaging.
|
Academic Article
|
Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs.
|
Academic Article
|
Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.
|
Academic Article
|
Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approach.
|
Academic Article
|
Role of ADP receptors on platelets in the growth of ovarian cancer.
|
Academic Article
|
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression.
|
Academic Article
|
Aspirin use and endometrial cancer risk and survival.
|
Academic Article
|
Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
|
Academic Article
|
Biobehavioral modulation of the exosome transcriptome in ovarian carcinoma.
|
Academic Article
|
Peroxisomes contribute to oxidative stress in neurons during doxorubicin-based chemotherapy.
|
Academic Article
|
MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels.
|
Academic Article
|
Trends of low-grade serous ovarian carcinoma in the United States.
|
Academic Article
|
Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.
|
Academic Article
|
Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial.
|
Academic Article
|
Diurnal cortisol rhythms, fatigue and psychosocial factors in five-year survivors of ovarian cancer.
|
Academic Article
|
Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.
|
Academic Article
|
DNA methylation signatures and coagulation factors in the peripheral blood leucocytes of epithelial ovarian cancer.
|
Academic Article
|
Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.
|
Academic Article
|
Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.
|
Academic Article
|
LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.
|
Academic Article
|
A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression.
|
Academic Article
|
Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.
|
Academic Article
|
Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis.
|
Academic Article
|
Association of biobehavioral factors with non-coding RNAs in cervical cancer.
|
Academic Article
|
Activating Transcription Factor 4 Modulates TGF?-Induced Aggressiveness in Triple-Negative Breast Cancer via SMAD2/3/4 and mTORC2 Signaling.
|
Academic Article
|
Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.
|
Academic Article
|
A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
|
Academic Article
|
Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer.
|
Academic Article
|
Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.
|
Academic Article
|
Perioperative inhibition of ?-adrenergic and COX2 signaling in a clinical trial in breast cancer patients improves tumor Ki-67 expression, serum cytokine levels, and PBMCs transcriptome.
|
Academic Article
|
Selective delivery of PLXDC1 small interfering RNA to endothelial cells for anti-angiogenesis tumor therapy using CD44-targeted chitosan nanoparticles for epithelial ovarian cancer.
|
Academic Article
|
When Ovarian Cancer Is Not: Characterizing Nonovarian Cancer Pathology in a Laparoscopy-Based Triage System.
|
Academic Article
|
FABP4 as a key determinant of metastatic potential of ovarian cancer.
|
Academic Article
|
CD44-Targeting PLGA Nanoparticles Incorporating Paclitaxel and FAK siRNA Overcome Chemoresistance in Epithelial Ovarian Cancer.
|
Academic Article
|
Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.
|
Academic Article
|
PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis.
|
Academic Article
|
Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
|
Academic Article
|
Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
|
Academic Article
|
Bone protection by inhibition of microRNA-182.
|
Academic Article
|
Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers.
|
Academic Article
|
PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.
|
Academic Article
|
Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
|
Academic Article
|
EGFL6 promotes breast cancer by simultaneously enhancing cancer cell metastasis and stimulating tumor angiogenesis.
|
Academic Article
|
Exploring and comparing adverse events between PARP inhibitors.
|
Academic Article
|
Performance of the MasSpec Pen for Rapid Diagnosis of Ovarian Cancer.
|
Academic Article
|
Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.
|
Academic Article
|
Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
|
Academic Article
|
Quaking orchestrates a post-transcriptional regulatory network of endothelial cell cycle progression critical to angiogenesis and metastasis.
|
Academic Article
|
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.
|
Academic Article
|
Predicting Novel Therapies and Targets: Regulation of Notch3 by the Bromodomain Protein BRD4.
|
Academic Article
|
Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach.
|
Academic Article
|
Small RNA Sequencing across Diverse Biofluids Identifies Optimal Methods for exRNA Isolation.
|
Academic Article
|
exRNA Atlas Analysis Reveals Distinct Extracellular RNA Cargo Types and Their Carriers Present across Human Biofluids.
|
Academic Article
|
Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53-altered tumors.
|
Academic Article
|
Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.
|
Academic Article
|
Pan-cancer genomic analysis links 3'UTR DNA methylation with increased gene expression in T cells.
|
Academic Article
|
Advancing Drug Development in Gynecologic Malignancies.
|
Academic Article
|
Identifying and targeting angiogenesis-related microRNAs in ovarian cancer.
|
Academic Article
|
Chromosomal Instability in Tumor Initiation and Development.
|
Academic Article
|
Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer.
|
Academic Article
|
Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
|
Academic Article
|
Anti-Angiogenesis Therapy in Ovarian Cancer: Which Patient is It Most Likely to Benefit?
|
Academic Article
|
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.
|
Academic Article
|
Placenta-derived extracellular vesicles induce preeclampsia in mouse models.
|
Academic Article
|
Social Integration, Marital Status, and Ovarian Cancer Risk: A 20-Year Prospective Cohort Study.
|
Academic Article
|
Clinical and biological significance of EZH2 expression in endometrial cancer.
|
Academic Article
|
A Solution to the Dilution: The Role for Biomarkers in Advanced Ovarian Cancer.
|
Academic Article
|
A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis.
|
Academic Article
|
Pan-cancer clinical and molecular analysis of racial disparities.
|
Academic Article
|
Effects of Gastrointestinal-Type Chemotherapy in Women With Ovarian Mucinous Carcinoma.
|
Academic Article
|
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
|
Academic Article
|
Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma.
|
Academic Article
|
Mechanisms of nuclear content loading to exosomes.
|
Academic Article
|
Predictors of survival trajectories among women with epithelial ovarian cancer.
|
Academic Article
|
Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.
|
Academic Article
|
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
|
Academic Article
|
GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
|
Academic Article
|
Evolving population-based statistics for rare epithelial ovarian cancers.
|
Academic Article
|
Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
|
Academic Article
|
Low-grade serous ovarian cancer: State of the science.
|
Academic Article
|
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
|
Academic Article
|
Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women.
|
Academic Article
|
Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer.
|
Academic Article
|
Significance of lymph node ratio on survival of women with borderline ovarian tumors.
|
Academic Article
|
Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
|
Academic Article
|
NRG1/ERBB3 Pathway Activation Induces Acquired Resistance to XPO1 Inhibitors.
|
Academic Article
|
Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer.
|
Academic Article
|
The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
|
Academic Article
|
Epithelial-mesenchymal transition polarization in ovarian carcinomas from patients with high social isolation.
|
Academic Article
|
OvCa-Chip microsystem recreates vascular endothelium-mediated platelet extravasation in ovarian cancer.
|
Academic Article
|
Blockade of the Short Form of Prolactin Receptor Induces FOXO3a/EIF-4EBP1-Mediated Cell Death in Uterine Cancer.
|
Academic Article
|
Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.
|
Academic Article
|
Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
|
Academic Article
|
Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer.
|
Academic Article
|
The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis.
|
Academic Article
|
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.
|
Academic Article
|
Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity.
|
Academic Article
|
Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
|
Academic Article
|
Targeting progesterone signaling prevents metastatic ovarian cancer.
|
Academic Article
|
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
|
Academic Article
|
Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer.
|
Academic Article
|
Gain-of-function p53 protein transferred via small extracellular vesicles promotes conversion of fibroblasts to a cancer-associated phenotype.
|
Academic Article
|
Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study.
|
Academic Article
|
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer.
|
Academic Article
|
PRKAR1B-AS2 Long Noncoding RNA Promotes Tumorigenesis, Survival, and Chemoresistance via the PI3K/AKT/mTOR Pathway.
|
Academic Article
|
Chronic difficulties are associated with poorer psychosocial functioning in the first year post-diagnosis in epithelial ovarian cancer patients.
|
Academic Article
|
The effect of platelet G proteins on platelet extravasation and tumor growth in the murine model of ovarian cancer.
|
Academic Article
|
CD8+ T cells inhibit metastasis and CXCL4 regulates its function.
|
Academic Article
|
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
|
Academic Article
|
Expression of B7-H4 and IDO1 is associated with drug resistance and poor prognosis in high-grade serous ovarian carcinomas.
|
Academic Article
|
Timing of surgery in patients with partial response or stable disease after neoadjuvant chemotherapy for advanced ovarian cancer.
|
Academic Article
|
Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity.
|
Academic Article
|
Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.
|
Academic Article
|
Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with biobehavioral factors.
|
Academic Article
|
Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment.
|
Academic Article
|
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
|
Academic Article
|
Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling.
|
Academic Article
|
CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance.
|
Academic Article
|
MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer.
|
Academic Article
|
Rural residence is related to shorter survival in epithelial ovarian cancer patients.
|
Academic Article
|
Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status.
|
Academic Article
|
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer.
|
Academic Article
|
Clinically translatable quantitative molecular photoacoustic imaging with liposome-encapsulated ICG J-aggregates.
|
Academic Article
|
Antihypertensive medication use and ovarian cancer survival.
|
Academic Article
|
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
|
Academic Article
|
The life cycle of polyploid giant cancer cells and dormancy in cancer: Opportunities for novel therapeutic interventions.
|
Academic Article
|
Attributions of survival and methods of coping of long-term ovarian cancer survivors: a qualitative study.
|
Academic Article
|
RNA-binding protein FXR1 drives cMYC translation by recruiting eIF4F complex to the translation start site.
|
Academic Article
|
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
|
Academic Article
|
Endothelial p130cas confers resistance to anti-angiogenesis therapy.
|
Academic Article
|
Longitudinal Changes in Bone Mineral Measurements Inside and Outside Radiation Fields Used for Cervical Cancer Treatment.
|
Academic Article
|
Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.
|
Academic Article
|
The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes.
|
Academic Article
|
Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex.
|
Academic Article
|
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
|
Academic Article
|
Antibody therapeutics for epithelial ovarian cancer.
|
Academic Article
|
Race-associated molecular changes in gynecologic malignancies.
|
Academic Article
|
Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.
|
Academic Article
|
Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
|
Academic Article
|
Classification of High-Grade Serous Ovarian Cancer Using Tumor Morphologic Characteristics.
|
Academic Article
|
Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer.
|
Academic Article
|
SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas.
|
Academic Article
|
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
|
Academic Article
|
Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors.
|
Academic Article
|
Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study.
|
Academic Article
|
Secondary Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy for Advanced or Recurrent Mucinous Ovarian Cancer.
|
Academic Article
|
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
|
Academic Article
|
Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
|
Academic Article
|
Leveraging mid-infrared spectroscopic imaging and deep learning for tissue subtype classification in ovarian cancer.
|
Academic Article
|
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer.
|
Academic Article
|
Low-grade serous ovarian cancer: expert consensus report on the state of the science.
|
Academic Article
|
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
|
Academic Article
|
The biology of hope: Inflammatory and neuroendocrine profiles in ovarian cancer patients.
|
Academic Article
|
EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer.
|
Academic Article
|
Phase 1b study of intraperitoneal ipilimumab and nivolumab in patients with recurrent gynecologic malignancies with peritoneal carcinomatosis.
|